Fatostatin (hydrobromide)
CAY-13562-5 5 mg
Data Sheet: 
SDS:
SDS:
CAS
298197-04-3
Formulation
A crystalline solid
Purity
≥95%
MW
375,3
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
Sterol regulatory element binding proteins (SREBPs) are transcription factors that have pivotal roles in lipogenesis and fat metabolism.{15316} The activation of SREBPs requires escort to the Golgi by SREBP cleavage-activating protein (SCAP) followed by proteolytic release of SREBP from the Golgi.{15551} Fatostatin is an inhibitor of SREBP activation, preventing SCAP-mediated escort of either SREBP-1 or SREBP-2 to the Golgi (IC50 = 5.6 µM).{17397,23867} This blocks constitutive SREBP-mediated gene expression in the human prostate cancer cell line DU145.{17397} Fatostatin prevents insulin-induced adipogenesis of 3T3-L1 cells as well as growth induced by insulin-like growth factor 1 in DU145 cells (IC50 = 0.1 µM).{23869} Through its actions on SCAP/SREBP-1, it inhibits high glucose-induced upregulation of TGF-β in primary rat mesangial cells.{23868} This compound also alters lipid metabolism in vivo, reducing hepatic fat accumulation in ob/ob mice.{17397}
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
